- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00917553
Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy (POC2)
October 30, 2018 updated by: Thomas Gardner
Proof-of-Concept 2 (POC2): Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Progression in Patients With Mild to Moderate Non-Proliferative Diabetic Retinopathy
This 24 month randomized research study will evaluate whether doxycycline can slow the deterioration or improve retinal function among patients with mild to moderate non-proliferative diabetic retinopathy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objective of this proof-of-concept study is to investigate whether doxycycline can slow the deterioration or improve retinal function among patients with mild to moderate NPDR (with abnormal retinal function defined as a foveal sensitivity < 30.91 dB on Matrix frequency doubling perimetry [FDP]).
Based on results of the END DR Study, the primary visual function endpoint in the POC 2 Study will be performance on the Matrix Frequency Doubling Technology Perimeter.
This test was the most sensitive to NPDR of the visual function endpoints the investigators evaluated in the END DR Study.
This selection is aggressive because the investigators lack natural history data to estimate the 2-year rate of change in the endpoint; in fact, a major output of this POC 2 Study will be 2-year natural history data using several visual function endpoints.
The investigators are enrolling patients who have moderate dysfunction; that is, patients who fall outside the 95% confidence interval of normal performance on FDP.
These patients will have the opportunity to improve their FDP performance to "normal" levels as well as progress to more severe FDP impairment associated with more advanced disease.
Secondary endpoints include visual acuity, contrast sensitivity, visual field, and dark adaptation.
The tests will be performed in the Ophthalmology Department of the Penn State College of Medicine.
The 24-month proof-of-concept clinical study will involve a prospective, randomized, double-masked clinical trial including 60 adult patients with type 1 or type 2 diabetes who have mild to moderate NPDR (ETDRS levels 20 to 43), and in whom retinal photocoagulation is not anticipated (by the investigator) within the subsequent 2 years.
Participants will be randomized to receive either doxycycline monohydrate 50mg or an identical placebo once daily for 24 months.
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Milton S. Hershey Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age ≥ 18 years old
- diagnosis of type 1 or type 2 diabetes mellitus (defined as current regular use of oral anti-hyperglycemia agents and/or insulin for the treatment of diabetes)
- have a hemoglobin A1c < 11% at pre-qualification visit
- able and willing to give informed consent
- best-corrected ETDRS visual acuity (10) in study eye ≥ 69 letters (20/40)
- mild to moderate non-proliferative diabetic retinopathy (ETDRS levels 20 to 43) (11), and in whom retinal photocoagulation is not anticipated (by the investigator) within the subsequent 2 years
- able to perform reliable visual field and dark adaptation testing
- central subfield thickness on OCT ≤ 275 microns
- media clarity and pupil dilation sufficient for high-quality fundus photographs
- abnormal retinal function defined as:
- abnormal FDP function as defined by a foveal sensitivity ≤ 30.91 dB
Exclusion Criteria:
- prior panretinal photocoagulation in the study eye
- prior focal/grid laser photocoagulation in the macula in the study eye
- intraocular pressure in the study eye > 22 mmHg by Goldmann tonometry
- history of pars plana vitrectomy in the study eye
- systemic or intravitreal anti-VEGF agent to the study eye or the fellow eye within the past 3 months
- peribulbar steroid injection to the study eye or the fellow eye within the past 6 months
- intravitreal triamcinolone acetonide to the study eye within the past 4 months
- expectation by the investigator that retinal photocoagulation or other treatment for diabetic retinopathy (e.g., focal/grid laser to study eye, intravitreal triamcinolone acetonide to study eye, intravitreal anti-VEGF agent to study or fellow eye, ruboxistaurin or systemic anti-VEGF agent for diabetic macular edema) will be administered in the subsequent 24months
- an ocular condition (other than diabetes) is present in the study eye that, in the opinion of the investigator, might alter visual acuity during the course of the study (e.g., retinal vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc)
- anticipated need for cataract surgery in the study eye in the subsequent 24 months in the opinion of the investigator
- history of major ocular surgery (including cataract surgery, scleral buckle, any intraocular surgery, etc) in the study eye within prior 6 months or anticipated within the subsequent 24 months following randomization
- aphakia in the study eye
- history of YAG capsulotomy performed in the study eye within 2 months prior to randomization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Cellulose Placebo Capsule
|
Experimental: doxycycline monohydrate
|
50 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group
Time Frame: Baseline and 24 months
|
Baseline and 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change Thickness Thickness
Time Frame: Baseline and 24 months
|
Anatomic outcomes were assessed through optical coherence.
Positive numbers indicate increases in thickness.
|
Baseline and 24 months
|
Change in Macular Volume
Time Frame: Baseline and 24 months
|
Baseline and 24 months
|
|
Number of Participants With Progression to PDR, and Single or Multiple Step Progression in ETDRS Diabetic Retinopathy Severity Level
Time Frame: Baseline to 24 months
|
Participants are shown categorically by whether they reached PDR, or whether their diabetic retinopathy levels changed by one grade or more, as analyzed by fundus photography.
|
Baseline to 24 months
|
Number of Participants Who Developed Vitreous or Preretinal Hemorrhage
Time Frame: 24 months
|
Any participants who developed vitreous or preretinal hemorrhage were counted.
Had there been any preretinal hemorrhages (a subcategory of vitreous hemorrhage) these would have been shown as a separate row.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Thomas W Gardner, MD.,MS., University of Michigan, Kellogg Eye Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Actual)
July 1, 2012
Study Completion (Actual)
July 1, 2012
Study Registration Dates
First Submitted
June 1, 2009
First Submitted That Met QC Criteria
June 9, 2009
First Posted (Estimate)
June 10, 2009
Study Record Updates
Last Update Posted (Actual)
November 30, 2018
Last Update Submitted That Met QC Criteria
October 30, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 30791
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
AEYE Health IncA. Stein Regulatory Affairs Consulting Ltd.RecruitingDiabetic Mellitus | Diabetic Retinopathy, DRUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
Clinical Trials on doxycycline monohydrate
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Teva Pharmaceuticals USACompleted
-
Teva Pharmaceuticals USACompleted
-
Thomas GardnerJuvenile Diabetes Research FoundationCompleted
-
PfizerCompleted
-
Medical College of WisconsinNational Heart, Lung, and Blood Institute (NHLBI)CompletedPrimary Systemic AmyloidosisUnited States
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
University of FloridaAlchem Laboratories, IncCompleted